

Technology Appraisal Committee B Interests Register

Topic: Fruquintinib for previously treated metastatic colorectal cancer [ID6274]

Publication Date: TBC.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Peter Wheatley	TAC B Committee Member	Direct - Financial Professional	Works for Takeda	12/12/2024 18/06/2024	It was agreed that Peter's declaration would prevent him from participating in discussions on this appraisal.
David McAlister	TAC B Committee Member	Non-Financial Professional	David uses trial data provided by the sponsors or their competitors via the Vivli trial platform for academic research.	12/12/2024 11/07/2024	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Sarah Milne	Patient Expert	Indirect - Financial	Bowel Cancer UK has received £37,832.0 from Takeda since February 2024 (nothing prior to this). We've also been granted a further £30K, however, we haven't had that in yet, but should be in the next few weeks. £10,000 was restricted to the National Colorectal Cancer Nurses	12/12/2024	It was agreed that Sarah's declaration would not prevent him from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Network (NCCNN). Also, £2K of the £37K was VAT.		
Mark Saunders	Clinical Expert	Direct Financial	Over the last 3 years Mark has received payment from Servier for lectures, meetings and to attend international meetings. Since April 2020, he has had 12 such meetings receiving £15,000.	12/12/2024 11/07/2024	It was agreed that Mark's declaration would not prevent him from providing expert advice to the committee.
Mark Saunders	Clinical Expert	Indirect Financial	Received a fee for a talk for BAYER at UK Oncology Forum in June 23 (£1912.50). I have been involved in 4 Takeda ad boards: Sep 23 - £2516.25, Oct 23 - £1525, Dec 23 - £2135 Feb 24 - £1220, GSK advice on survey, Dec 23 - £580. MSD ad board Nov 22 - £1680 Received a fee for a talk for BAYER at UK Oncology Forum in June 23 (£1912.50).	12/12/2024 11/07/2024	It was agreed that Mark's declaration would not prevent him from providing expert advice to the committee.
Harpreet Wasan	Clinical Expert	Direct Financial	Harpreet has been on a remunerated advisory Board for Takeda in the UK in the 2023 and	12/12/2024 11/07/2024	It was agreed that Harpreet's declaration would not prevent him

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			also been sponsored (paid) for meeting attendance at ESMO 2023 All values less than £3000		from providing expert advice to the committee.
Harpreet Wasan	Clinical Expert	Indirect Financial	Over the last 20 years, Harpreet has been on advisory boards and have done educational development work and invited talks on colorectal cancer for many organisations including drugs recently approved in Colorectal cancer by NICE: Regorafenib (BAYER), Trifluridine-tipiracil (SERVIER), Encorafenib, Binimetinib and Cetuximab in BRAFV600E CRC (Array then Pfizer).	12/12/2024 11/07/2024	It was agreed that Harpreet's declaration would not prevent him from providing expert advice to the committee.